Results 221 to 230 of about 10,365 (241)

Proliferative vitreoretinopathy and chemotherapeutic agents

Survey of Ophthalmology, 1985
Proliferative vitreoretinopathy (PVR) is a disease process that occurs in eyes with rhegmatogenous retinal detachments and accounts for the majority of failures following retinal detachment surgery. PVR involves the uncontrolled proliferation of non-neoplastic cells capable of forming membranes, which may occur on either surface of the retina or along ...
Joel A. Schulman, Gholam A. Peyman
openaire   +3 more sources

Interventions for Proliferative Vitreoretinopathy

JAMA Ophthalmology
Clinical QuestionWhat is the efficacy of pharmacologic interventions in preventing proliferative vitreoretinopathy?Bottom LineThere is limited high-quality evidence to support currently available pharmacological options for prevention of proliferative vitreoretinopathy.
Wilson X, Wang, Maggie, Xing, Rajendra S, Apte   +2 more
openaire   +2 more sources

Surgical Results for Proliferative Vitreoretinopathy [PDF]

European Journal of Ophthalmology, 1994
We reviewed 88 consecutive eyes that underwent vitrectomy for retinal detachment with proliferative vitreoretinopathy (PVR) and were followed a minimum of six months. A primary goal of the surgery was the meticulous trimming of the vitreous base in hopes of decreasing the incidence of postoperative reproliferation and anterior PVR.
D. Madeira, Howard Schatz, Robert N. Johnson, H. R. Mcdonald   +3 more
openaire   +2 more sources

Spontaneous resolution of proliferative vitreoretinopathy

Acta Ophthalmologica, 1992
Abstract A case of proliferative vitroretinopathy that spontaneously regressed, leading to reattachment of the retina, is presented. The importance of such a spontaneous resolution in terms of understanding the pathogenesis, and planning a treatment, is discussed.
Anat Loewenstein, Yehoshua Almog, Rivka Bracha, Moshe Lazar   +3 more
openaire   +3 more sources

Risk factors for proliferative vitreoretinopathy

Progress in Retinal and Eye Research, 1998
Proliferative vitreoretinopathy (PVR) is one of the major causes of failure in retinal detachment surgery. To prevent PVR, it is necessary to determine factors predisposing its development. In primary PVR, large retinal tears, long duration of retinal detachment, vitreous hemorrhages, aphakia and choroidal detachment were demonstrated as clinical risk ...
Manabu Mochizuki, Kouichi Shinagawa, Hiroshi Nagasaki   +2 more
openaire   +2 more sources

Current Management of Proliferative Vitreoretinopathy

Seminars in Ophthalmology, 1995
The recognition of APVR and its dissection, along with the use of perfluorocarbon liquids, has greatly improved the success rate in surgery for severe PVR. In reviewing our first 71 cases using these techniques, 75% were attached with one operation and 90% were attached with one or more operations.
H. M. Lambert, F. J. LoRusso, R. Diaz-Rohena, J. W. Thomas   +3 more
openaire   +3 more sources

Management of Proliferative Vitreoretinopathy

2015
Proliferative vitreoretinopathy (PVR) is the clinical syndrome associated with retinal traction and detachment in which cells with proliferative potential multiply and contract on retinal surfaces and in the vitreous compartment. PVR presents with a broad spectrum of severity ranging from subtle retinal wrinkling to a total rigid retinal detachment ...
D. Velázquez-Villoria, J. García-Arumi
openaire   +2 more sources

RUBEOSIS OF THE IRIS IN PROLIFERATIVE VITREORETINOPATHY

RETINA, 1996
The authors report the findings and clinical course of rubeosis in patients with essentially reattached retinas after vitrectomy and silicone oil for proliferative vitreoretinopathy (PVR).From 1989 on, the authors prospectively noted all patients with rubeosis and with attached retina posterior to the buckle after vitrectomy and silicone oil for PVR as
Diane A. E. Mertens, Ed Peperkamp, Jan C. van Meurs, Peter W.T de Waard, Boujola J. P. Bolt   +4 more
openaire   +3 more sources

Pharmacological therapy for proliferative vitreoretinopathy

Graefe's Archive for Clinical and Experimental Ophthalmology, 1986
We developed an animal model in the rabbit eye with intravitreally injected heterotransplanted bovine retinal pigment epithelial cells to test a pharmacological agent which would reduce extracellular matrix formation. Results with 20 and 60 micrograms of cis-hydroxyproline showed a 48% decrease in the rate of traction retinal detachments.
R J Ballou, A D Weinsieder, N D Radtke
openaire   +3 more sources

Proliferative Vitreoretinopathy

Ophthalmology, 2007
Gaetano Barile, Stanley Chang, William Schiff   +2 more
openaire   +3 more sources